论文部分内容阅读
目的探讨莫西沙星(moxifloxacin,MXFX)治疗广泛耐多药肺结核(extensively drug Resistance-tuberculosis,XDR-TB)的可行性。方法选取98例XDR-TB患者,随机分为莫西沙星(MXFX)组和左氧氟沙星(levofloxacin,LVFX)组,各49例。2组均采用常规抗结核药物,MXFX组加用莫西沙星,LVFX组加用左氧氟沙星,观察2组治疗效果。结果 MXFX组在治疗后4个月、12个月、18个月的痰菌转阴率均高于同期的LVFX组(79.59%vs 59.18%,P<0.05;89.79%vs 73.47%,P<0.05;95.92%vs 81.63%,P<0.05);病灶吸收率(93.88%)高于LVFX组(79.51%)(P<0.05);2组不良反应率对比差异无统计学意义(14.29%vs 16.32%,P>0.05)。结论采用MXFX治疗XDR-TB,病灶吸收率高,生物利用度高,疗效显著。
Objective To investigate the feasibility of moxifloxacin (MXFX) in the treatment of extensively drug-resistant tuberculosis (XDR-TB). Methods Ninety-eight patients with XDR-TB were randomly divided into four groups: MXFX group and levofloxacin group. Both groups were treated with conventional anti-TB drugs, MXFX plus moxifloxacin, and LVFX plus levofloxacin. The effects of two groups were observed. Results The negative conversion rate of sputum in 4, 12 and 18 months after treatment in MXFX group was significantly higher than that in the LVFX group (79.59% vs 59.18%, P <0.05; 89.79% vs 73.47%, P <0.05 ; 95.92% vs 81.63%, P <0.05); The rate of lesion absorption (93.88%) was higher than that of LVFX group (79.51%) (P <0.05); There was no significant difference in adverse reaction rate between the two groups (14.29% vs 16.32% , P> 0.05). Conclusion MXFX treatment of XDR-TB, high absorption rate of the lesion, high bioavailability, significant effect.